RoHS 3 Impact on Medical Devices



Description: picture of  green stop sign with "RoHS"
Resources

RoHS 2 vs RoHS 3 Impact on Medical Devices

TL;DR

RoHS 3 amends RoHS 2 by adding four phthalate plasticizers to the restricted substance list, with medical devices given an extended compliance timeline:

  • RoHS 3 expands the restricted substance list from six to ten by adding four phthalates: DEHP, BBP, DBP, and DIBP join the original six substances, all used as plasticizers in materials like PVC, vinyl flooring, adhesives, and PMMA.
  • Medical devices received an extended compliance deadline for the four new substances: general EEE had to comply by July 22, 2019, while medical devices and in vitro diagnostics, already required to meet RoHS 2, had until July 22, 2021.
  • Spare parts compliance follows the same placed-on-market cutoff as the parent device: cables and spare parts for devices placed on the market before each respective deadline remain exempt from the new substance restrictions.

Note: RoHS 3 is a colloquial term referring to Delegated Directive (EU) 2015/863, which is actually an amendment to RoHS 2 (Directive 2011/65/EU) rather than a standalone Directive. Though this terminology has become somewhat common (common enough to keep using the term here), it’s technically inaccurate. Originally published in April 2016, the article is updated on March 2, 2021 to include more details on the July 22, 2021 deadline. 

RoHS 3 – The Trilogy is Complete

Are your medical devices RoHS compliant?

The Restriction of Hazardous Substances (RoHS) Directive has had a substantial and permanent effect on the materials that go into many of the electronic products we make.

The original RoHS legislature (2002/95/EC), was released in 2002, and it restricts the amount of six substances (the first six on the list below) to only trace amounts in Electric and Electronic Equipment (EEE). In 2011, RoHS 2 (formally known as directive 2011/65/EU), replaced the original RoHS 1 legislature, by updating the scope and applicable types of products. Then, RoHS 2 was given a substantial update in the form of Delegated Directive (EU) 2015/863 to add four new substances and become what is colloquially known as RoHS 2.1 or RoHS 3 (they are the same thing).

Are your medical devices compliant with the latest changes?

RoHS 3 (EU 2015/863) expands the list of prohibited substances from six to ten by adding four new types of phthalates. This directive has been adopted by the EU legislature and came into full force on the 22nd of July 2019 with a special provision for medical devices until 2021 (see below for details). The final list of substance is as follows:

  • Lead (0.1 %)
  • Mercury (0.1 %)
  • Cadmium (0.01 %)
  • Hexavalent chromium (0.1 %)
  • Polybrominated biphenyls (PBB) (0.1 %)
  • Polybrominated diphenyl ethers (PBDE) (0.1 %)
  • Bis(2-ethylhexyl) phthalate (DEHP) (0.1 %)
  • Butyl benzyl phthalate (BBP) (0.1 %)
  • Dibutyl phthalate (DBP) (0.1 %)
  • Diisobutyl phthalate (DIBP) (0.1 %)

The 4 new members of the party that were added in RoHS 3 are all phthalates that are used as plasticizers, and are thankfully already banned or restricted in many parts of the world. DEHP accounts for a more than half of the plasticizer industry, for example making up 60% in the Asia Pacific market. It is also heavily prevalent in PVC, which for this reason and others is quickly becoming an unwise choice of plastics in the design of EEE. BBP is widely used in vinyl floor tiles, but can also be found in caulking and adhesives. DBP can also be used in adhesives and in inks. DIBP is used in making PMMA (commonly known as acrylic or Plexiglas) plastic.

Newsletter Sign-up
CASL Opt-in

How does RoHS compliance pertain to medical devices?

Interestingly, medical devices have special rules for these four substances:

The restriction of DEHP, BBP, DBP and DIBP shall apply to medical devices, including in vitro medical devices, and monitoring and control instruments, including industrial monitoring and control instruments, from 22 July 2021.

Medical devices, therefore, have until 22 July 2021 to comply with RoHS 3 (rather than 22 July 2019). Note that medical devices are already required to comply with RoHS 2. Lastly, we get to the big question: what about your existing products?

The restriction of DEHP, BBP, DBP and DIBP shall not apply to cables or spare parts for the repair, the reuse, the updating of functionalities or upgrading of capacity of EEE placed on the market before 22 July 2019…

So current devices in the field will be exempt as far as spare parts (i.e., cables) are concerned, but EEE sales after 22 July 2019 will need their spare parts to comply with the directive.

…and of medical devices, including in vitro medical devices, and monitoring and control instruments, including industrial monitoring and control instruments, placed on the market before 22 July 2021.

Therefore, spare parts only need to comply with RoHS 3 for medical devices placed on the market after 22 July 2021.

If you haven’t done so already, I would highly encourage designers to source materials and components that are RoHS3 compliant right away – it’s the law. Knowing what to look for and finding good vendors with appropriate quality programs will lead to a smoother product development program and faster time to market.

Nigel Syrotuck is a StarFish Medical Project Engineer.  He works on projects big and small and blogs on everything in-between. This is his first RoHS blog for StarFish Medical, but not his last.

Image: 2641435 © Wayne Ruston | Dreamstime.com

Businessman holding a glowing compliance icon with legal and regulatory symbols, representing REACH SVHC compliance for medical device manufacturers

Nigel Syrotuck breaks down REACH SVHC compliance for teams working with material suppliers and compliance questionnaires.

medical vs wellness device example showing alert vs no alert functionality

This medical vs wellness example shows how device classification can directly change functionality. Even when hardware is similar, what the device is allowed to do can be very different.

Engineers conducting pre-clinical testing of a novel medical device in a controlled laboratory environment

For manufacturers of novel devices that can make a significant impact to patient health, the goal of the program is to offer a path to streamlined and potentially faster market entry without sacrificing the rigour around ensuring safety and performance.

Medical device data management displayed on a connected healthcare tablet

When I was starting out in medical devices, the discussion focused on the possibility of an internet of things and the promise of “big data” about everything.

Explore Our Services

Illustration of a pencil and ruler

Our multidisciplinary teams have all the in-house capabilities to transform your medical device from concept to final product.

Illustration of a 3D cube

Medical device design and development with a commercial launch focus. See how we support clinical trials and facilitate seamless tech transfers.

Illustration of two speech bubbles

We help you navigate complex regulatory landscapes to achieve commercial success. Explore our integrated approach to quality and regulatory services.